Treadmill Training and Quality of Life in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00890669|
Recruitment Status : Completed
First Posted : April 30, 2009
Last Update Posted : May 4, 2009
Parkinson's disease (PD) causes motor and non-motor impairments that affect the quality of life of the subjects. The purpose was to assess the effects of treadmill walking training with additional body load on the quality of life and motor symptoms of the subjects with PD.
Methods: Nine subjects with PD, Hoehn and Yahr stages 2 through 3, not demented and with capability to ambulate independently voluntarily participate in this study. The training program was divided into three phases (A1-B-A2): treadmill training with additional body load (A1), control condition (conventional physical therapy group) (B) and treadmill training with load again (A2). Each phase lasted six weeks. The quality of life and motor symptoms were assessed by PDQ-39 and UPDRS, respectively. Both evaluations and training were performed during on-phase of the medication cycle.
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease||Other: Treadmill walking training with additional body load||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treadmill Walking Training With Additional Body Load Improves Quality of Life in Subjects With Parkinson's Disease|
|Study Start Date :||August 2007|
|Actual Study Completion Date :||December 2008|
Experimental: PD Group
Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
Other: Treadmill walking training with additional body load
The training program was divided into three phases (A1-B-A2):
Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle.
- The quality of life was measured through Parkinson Disease Questionnaire (PDQ-39). [ Time Frame: 4 times, once before treatment, and 3 after each treatment phase. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00890669
|Universidade Federal de São Carlos|
|São Carlos, SP, Brazil, 13565-905|
|Principal Investigator:||Nadiesca T Filippin, MSc||Universidade Federal de Sao Carlos|
|Study Chair:||Rosana Mattioli, PhD||Universidade Federal de Sao Carlos|
|Study Director:||Paula H Lobo da Costa, PhD||Universidade Federal de Sao Carlos|